NeurAxon Raises $32 Million

NeurAxon Inc., a drug company focused on pain management, has raised $32 million in Series B funding. Delphi Ventures and Orbimed Advisors co-led the deal, and were joined by return backers BDC Venture Capital, Genesys Capital Partners, H.I.G. Ventures, NeuroVentures Fund and Ventures West Capital. The company has offices in both Waltham, Mass. and Toronto.